Figure 5.

Molecular analysis of minor salivary gland biopsies in the rituximab and disease-modifying anti-rheumatic drug treatment groups. Relative mRNA quantification of (A) LTα, (B) LTβ, (C) CXCR4, (D) CXCL12, (E) CXCR5, (F) CXCL13, and (G) B-cell activating factor (BAFF) was assessed by quantitative real-time polymerase chain reaction in salivary glands obtained from 41 pSS patients and five healthy donors (HD). Bars indicate mean ± standard error of the mean. Levels are expressed as the fold increase or decrease in pSS MSGs compared with HD MSGs. ***P <0.001; **P <0.01 and *P <0.05. DMARD, disease-modifying anti-rheumatic drug; LT, lymphotoxin; RTX, rituximab.

Carubbi et al. Arthritis Research & Therapy 2013 15:R172   doi:10.1186/ar4359
Download authors' original image